Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TERT | O14746 | 5/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | RECQL | P46063 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | TRPV1 | Q8NER1 | 3/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6784464 | 0.91 | TERT (0.53) | TERT | |
| SCHEMBL6786749 | 0.86 | TERT (0.52) | TERTLMNAGAATSHRRECQL | |
| SCHEMBL6790208 | 0.86 | TERT (0.51) | TERTLMNATRPV1 | |
| SCHEMBL6787305 | 0.83 | TERT (0.53) | TERTLMNAGAATSHRRECQL | |
| SCHEMBL6784470 | 0.83 | TERT (0.48) | TERTLMNAGAATSHRRECQL | |
| SCHEMBL6786754 | 0.82 | TERT (0.53) | TERTLMNAGAATSHRRECQL | |
| SCHEMBL6782364 | 0.82 | TERT (0.52) | TERTLMNAGAATSHRRECQL | |
| SCHEMBL6791658 | 0.81 | TERT (0.47) | TERTLMNATSHRSMN1; SMN2 | |
| SCHEMBL6784141 | 0.80 | TERT (0.58) | TERTLMNAGAATSHRRECQL | |
| SCHEMBL6787120 | 0.79 | TERT (0.55) | TERTLMNAGAATSHRRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6727250-B2 | ADMINISTERING COMPOUNDS SUCH AS TRANS-3-(NAPHTH-2-YL)-BUT-2-ENOIC ACID-N-(2-CARBOXY-PHENYL)-AMIDE OR LIKE FOR THERAPY OF CONDITIONS ASSOCIATED WITH INCREASED TELOMERASE ACTIVITY, E.G. TUMOUR DISEASES | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2004-04-27 | — | — | US | disclosed |
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-07-25 | — | — | US | disclosed |
| US-6362210-B1 | ANTITUMOR, ANTICANCER AGENT | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2002-03-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020099089-A1 | Carboxylic acid amides, pharmaceutical compositions containing these compounds, their use and preparation | TERT, NAT1, POT1 | TERT 1/4885LMNA 169/4885GAA 262/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.